Literature DB >> 2219962

Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor.

L Grislain1, M T Mocquard, J F Dabe, M Bertrand, W Luijten, B Marchand, G Resplandy, M Devissaguet.   

Abstract

1. The metabolism of perindopril (non-thiol angiotensin-converting enzyme inhibitor) was studied in rat, dog and monkey after single oral and i.v. administration of 14C-perindopril, and in man after a single oral dose. 2. Six biotransformation products of perindopril from urine, faecal and plasma samples (bile only for rats) were identified. 3. The main route of biotransformation in all species is the hydrolysis of the carboxylic ethyl ester side-chain, with the formation of perindoprilate, the active metabolite. 4. A minor route of biotransformation led to the acyl glucuronides of perindopril and perindoprilate. 5. Internal dehydration of perindopril and perindoprilate into cyclic lactam structures occurs. This route of metabolism is of minor importance except in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219962     DOI: 10.3109/00498259009046893

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

2.  Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats.

Authors:  Seok-Bong Kang; Ho-Sang Shon; Soo-Jin Park; Chang-Hyun Song; Sae-Kwang Ku
Journal:  Biomed Rep       Date:  2014-08-05

Review 3.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.